Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Puma's Neratinib Gets CHMP Turnaround But Slow EU Uptake Expected

Executive Summary

Puma Biotech has proven to be the cat with nine lives after its HER2+ breast cancer treatment neratinib received a u-turn from CHMP, granting it a positive trend vote. But even if final marketing approval is granted this year, European prospects don’t necessarily follow.

Advertisement

Related Content

Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More
Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology
Herceptin, Enbrel Face First Biosimilar Rivals In Japan But Outlook Uncertain
Zero Success For Companies Appealing Negative CHMP Opinions In EU Last Year
Puma's Likely Neratinib EU Knockback May Be Temporary
Roche Digs In To Early Breast Cancer With New Perjeta Approvals
APHINITY Combo Details Contain No Surprise, Puma's Nerlynx May Benefit

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel